Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04693533 · ClinicalTrials.gov registry record · Phase 4
Fremanezumab, Migraine and Sleep
A Phase 4 study, sponsored by Beth Israel Deaconess Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
NCT04693533 is a Phase 4 study that was terminated before completion, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 22 participants.
The verdict
NCT04693533, a Phase 4 study, was terminated before completion, sponsored by Beth Israel Deaconess Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
Study Summary
The main goal of this study is to determine whether there is a relationship between fremanezumab's ability to prevent migraine and improved sleep quality in migraine patients (fremanezumab is a FDA-approved humanized CGRP monoclonal antibody for the treatment of migraine). This is a within-person study design that examines treatment effects (changes) using high-resolution assessments. To complete the study, each participant will be observed using daily assessments of migraine and sleep outcomes before treatment (baseline: 0 to 30 days), and at 1, 2, and 3 months after treatment (injection 1: days 31-60, injection 2: days 61-90, injection 3: days 91-120). In essence, this creates an interrupted time-series design where repeated interventions are introduced at fixed intervals.
Interventions
- DRUG Fremanezumab Prefilled Syringe [Ajovy]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2021-07-29 |
| Est. Completion | 2024-04-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04693533
The ClinicalTrials.gov registry entry for NCT04693533 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fremanezumab Prefilled Syringe [Ajovy] is the first listed.
NCT04693533 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04693533 about?
NCT04693533 is a clinical study titled "Fremanezumab, Migraine and Sleep". The main goal of this study is to determine whether there is a relationship between fremanezumab's ability to prevent migraine and improved sleep quality in migraine patients (fremanezumab is a FDA-approved humanized CGRP monoclonal antibody for the treatment of migraine). This is a within-person s...
What is the current status of trial NCT04693533?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2021-07-29. Estimated completion is 2024-04-01.
What interventions are being tested in trial NCT04693533?
The interventions under investigation include: Fremanezumab Prefilled Syringe [Ajovy] (DRUG).
Who is sponsoring clinical trial NCT04693533?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.